Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Which dialysis dose saves more lives in the ICU? a trial seeks answers

NCT ID NCT06014801

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This trial asks whether a lower or medium intensity of continuous kidney replacement therapy (dialysis) is better for critically ill patients with acute kidney injury. It will compare a low dose (12 mL/kg/hr) against a standard medium dose (25 mL/kg/hr) to see which is more effective and safer. The study includes 400 adults in intensive care units and will track outcomes like death and how long patients need dialysis.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Continuous kidney replacement therapy (dialysis/filtration) at low or medium intensity
What this could lead to
If successful, this could identify the optimal dialysis intensity for ICU patients with acute kidney injury, potentially improving survival and reducing time on dialysis.
What could go wrong
This is a mid-stage trial, and results may not apply to all ICU patients. There are inherent risks of dialysis, such as infection or blood pressure changes, and the optimal intensity may vary by patient.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2023

Expected to finish

Jun 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patient who meets all of the following criteria and who has given informed consent. 1. Adults (18 years of age or older, regardless of the time since ICU admission) currently admitted to an intensive care unit\*. \*Includes high care units, where continuous monitoring is conducted and intensive care physicians are in charge of medical care. 2. A diagnosis of acute kidney injury is made according to the Kidney Disease: Improving Global Outcomes (KDIGO) international diagnostic criteria (one of the following is met) * Serum creatinine increased by more than 0.3 mg/dL within 48 hours * Serum creatinine increased more than 1.5-fold from baseline and the increase is considered to have occurred within 7 days * Oliguria (\< 0.5 mL/kg/hr) lasting more than 6 hours 3. The treating intensivist believes that continuous kidney replacement therapy is necessary Exclusion Criteria: Patient who meets any of the following exclusion criteria will be excluded. 1. Receiving chronic dialysis or scheduled for initiation of chronic dialysis 2. Undergoing any kidney replacement therapy or blood purification therapy within 48 hours 3. When kidney replacement therapy using other dialysate or replacement fluids, such as citrate dialysis, is preferred due to coexisting bleeding disorders or allergy to acetate 4. Concomitant blood purification therapy other than hemofiltration/dialysis, such as plasma exchange 5. The patient is in a very critical condition and the treating physician believes that survival for more than 24 hours is unlikely 6. Previous participation in the study 7. After receiving a full explanation of the study and with full understanding, a patient do not consent to participate in the study of their own (or their substitute decision maker's) will. 8. The principal investigator (or an investigator) thinks it to be inappropriate to participate in this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute kidney injury requiring continuous renal replacement therapy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    9 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Jichi Medical University Hospital

    RECRUITING

    Tochigi, 329 0498, Japan

  • Jikei University Hospital

    RECRUITING

    Tokyo, 105 8471, Japan

  • Keio University Hospital

    RECRUITING

    Tokyo, 160 0016, Japan

  • Osaka Medical and Pharmaceutical University Hospital

    RECRUITING

    Takatsuki, Osaka, 569-8686, Japan

  • Osaka University Hospital

    NOT_YET_RECRUITING

    Osaka, 565 0871, Japan

  • Sendai Medical Center

    RECRUITING

    Sendai, Miyagi, 983-8520, Japan

  • Tsuchiura Kyodo General Hospital

    RECRUITING

    Ibaraki, 300 0028, Japan

  • University of Fukui Hospital

    RECRUITING

    Fukui, 910 1193, Japan

  • Wakayama Medical University Hospital

    RECRUITING

    Wakayama, 641 8509, Japan